AI in drug discovery

News

Now Iktos teams up with Pierre Fabre in oncology

As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos

News

Iktos' Chemspeed robotics-powered chemistry platform

Servier signs €1bn-plus AI pact with Iktos

In its second AI-focused drug discovery deal in the space of a week, Servier has announced a €1bn partnership with France's Iktos.

News

Insilico Medicine and Servier logos on a black background

Insilico adds Servier to partnership roster with $888m deal

Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.

R&D

From complexity to cohesion: AI’s growing role in building s...

AI is being used from protocol design to study start-up and through clinical trial closeout, reshaping the trial lifecycle.

News

Insilico ends 2025 with $293m Hong Kong IPO

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

Digital

pharmaphorum podcast Episode 231, Dr Alan Roth, Oxford Drug Design

On AI and computational support of biochemistry, with Alan R...

Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.

Now Iktos teams up with Pierre Fabre in oncology

Servier signs €1bn-plus AI pact with Iktos

Insilico adds Servier to partnership roster with $888m deal

From complexity to cohesion: AI’s growing role in building s...

Insilico ends 2025 with $293m Hong Kong IPO

On AI and computational support of biochemistry, with Alan R...

J&J jumps on the MFN pricing train

How to meet your physicians where they are online

AI in drug discovery

Editor's Picks